• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

    11/14/24 8:41:06 AM ET
    $ABUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABUS alert in real time by email
    SC 13G/A 1 form_sc13ga-arbutus.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _____________________________________

    Schedule 13G

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO § 240.13d-2
    (Amendment No. 2)*  
    _____________________________________

    Arbutus Biopharma Corporation
    (Name of Issuer)

    Common Shares, without par value
    (Title of Class of Securities)

    03879J100
    (CUSIP Number)

    September 30, 2024
    (Date of Event which Requires Filing of this Statement)
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

    CUSIP No. 03879J100
                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital LP
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (5) 
      
    Sole Voting Power
     
    8,387,388
      
      (6)
      
    Shared Voting Power
     
    0
      
      (7)
      
    Sole Dispositive Power
     
    8,387,388
      
      (8)
      
    Shared Dispositive Power
     
    0
    (9)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    8,387,388
    (10)
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):  ☐
     
    (11)
     
    Percent of Class Represented by Amount in Row (9):
     
    4.4%*
    (12)
     
    Type of Reporting Person (See Instructions):
     
    IA, PN
     
    *
    Based on 189,438,135 Common Shares, without par value (“Common Shares”), of Arbutus Biopharma Corporation (the “Issuer”) outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on November 6, 2024.



    CUSIP No. 03879J100
                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital GP LLC
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (5) 
      
    Sole Voting Power
     
    8,387,388
      
      (6)
      
    Shared Voting Power
     
    0
      
      (7)
      
    Sole Dispositive Power
     
    8,387,388
      
      (8)
      
    Shared Dispositive Power
     
    0
    (9)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    8,387,388
    (10)
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):  ☐
     
    (11)
     
    Percent of Class Represented by Amount in Row (9):
     
    4.4%*
    (12)
     
    Type of Reporting Person (See Instructions):
     
    OO, HC
     
    *
    Based on 189,438,135 Common Shares of the Issuer outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024.



    CUSIP No. 03879J100
                 
      (1) 
     
    Name of Reporting Persons:
     
    Sina Toussi
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (5) 
      
    Sole Voting Power
     
    8,387,388
      
      (6)
      
    Shared Voting Power
     
    0
      
      (7)
      
    Sole Dispositive Power
     
    8,387,388
      
      (8)
      
    Shared Dispositive Power
     
    0
    (9)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    8,387,388
    (10)
     
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):  ☐
     
    (11)
     
    Percent of Class Represented by Amount in Row (9):
     
    4.4%*
    (12)
     
    Type of Reporting Person (See Instructions):
     
    IN, HC

    *
    Based on 189,438,135 Common Shares of the Issuer outstanding as of September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 6, 2024..

    Item 1(a)
    Name of Issuer:

    Arbutus Biopharma Corporation (the “Issuer”)
     
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:

    701 Veterans Circle
    Warminster, PA 18974
     
    Item 2(a)
    Name of Person Filing:

    The Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)

     
    i)
    Two Seas Capital LP (“TSC”);
     
     
     
     
    ii)
    Two Seas Capital GP LLC (“TSC GP”); and
     
     
     
     
    iii)
    Sina Toussi.

    This statement relates to Common Shares (as defined in Item 2(d) below) held by Two Seas Global (Master) Fund LP (the “Global Fund”) and Two Seas LNP Opportunities (Master) Fund LP (the “Opportunities Fund”, and together with the Global Fund, the “Funds”). The principal business of TSC is providing investment advice as a registered investment adviser and serving as investment manager to the Funds and other advisory clients. As such, TSC has been granted investment discretion over portfolio investments, including the Common Shares, held by or for the account of the Funds, including the Funds’ voting and discretionary decisions. TSC GP serves as general partner of TSC. Sina Toussi serves as the Chief Investment Officer of TSC and Managing Member of TSC GP.
     
    Item 2(b)
    Address of Principal Business Office or, if none, Residence:

    The address of the principal business office of each of the Reporting Persons is 32 Elm Place, 3rd Floor, Rye, New York 10580.
     
    Item 2(c)
    Citizenship:
     
     
    i)
    Two Seas Capital LP is a Delaware limited partnership;
     
     
     
     
    ii)
    Two Seas Capital GP LLC is a Delaware limited liability company; and
     
     
     
     
    iii)
    Sina Toussi is a United States citizen.
     
    Item 2(d)
    Title of Class of Securities:

    Common Shares, without par value (the “Common Shares”)
     
    Item 2(e)
    CUSIP No.:

    03879J100

    Item 3
    If this statement is filed pursuant to §§ 240 13d-1(b), or 240 13d-2(b) or (c), check whether the person filing is a:
     
     
     
     
     
     
    (a)
     
    ☐
     
    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
     
     
     
    (b)
     
    ☐
     
    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
     
     
     
    (c)
     
    ☐
     
    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
     
     
     
    (d)
     
    ☐
     
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
     
     
     
    (e)
     
    ☒
     
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
     
     
    (f)
     
    ☐
     
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
     
     
    (g)
     
    ☒
     
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
     
     
     
    (h)
     
    ☐
     
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);



     
     
     
    (i)
     
    ☐
     
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
     
     
    (j)
     
    ☐
     
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
     
     
    (k)
     
    ☐
     
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).
     
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution.
     
    Item 4
    Ownership:
     
    (a)
    Amount beneficially owned:

    TSC - 8,387,388 Common Shares
    TSC GP - 8,387,388 Common Shares
    Sina Toussi - 8,387,388 Common Shares

    (b)
    Percent of class:

    TSC - 4.4%
    TSC GP - 4.4%
    Sina Toussi - 4.4%

    (c)
    Number of shares as to which TSC has:

    (i) Sole power to vote or to direct the vote: 8,387,388
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 8,387,388
    (iv) Shared power to dispose or to direct the disposition of: 0


    Number of shares as to which TSC GP has:

    (i) Sole power to vote or to direct the vote: 8,387,388
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 8,387,388
    (iv) Shared power to dispose or to direct the disposition of: 0


    Number of shares as to which Sina Toussi has:

    (i) Sole power to vote or to direct the vote: 8,387,388
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or to direct the disposition of: 8,387,388
    (iv) Shared power to dispose or to direct the disposition of: 0

    The Common Shares reported for Item 4 total 8,387,388, of which 5,196,668 are held by the Global Fund and 3,190,720 are held by the Opportunities Fund. TSC may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as investment adviser of the Funds. TSC GP may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through its capacity as general partner of TSC. Sina Toussi may be deemed to have sole power to vote and sole power to dispose of the Common Shares held by the Funds, through his capacity as Managing Member of TSC GP.

    The percentages reported for Item 4(b) are calculated based on a total of 189,438,135 Common Shares outstanding on September 30, 2024, as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024.




    Item 5
     Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class securities, check the following ☒.
     
    Item 6
    Ownership of More Than Five Percent on Behalf of Another Person:

    See disclosure in Item 4, which is incorporated by reference herein.
     
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

    See disclosure in Item 2, which is incorporated by reference herein.
     
    Item 8
      Identification and Classification of Members of the Group:

    This Item 8 is not applicable.
     
    Item 9
      Notice of Dissolution of Group:

    This Item 9 is not applicable.

    Item 10
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.
     
     
     
     
     
     
     
     
    Dated: November 14, 2024
     
     
     
     
     
    Two Seas Capital LP
     
     
     
     
     
     
     
     
     
     
    By Two Seas Capital GP LLC, its General Partner
     
     
     
     
     
     
     
     
     
     
    By: /s/ Sina Toussi
     
     
     
     
     
     
    Sina Toussi
     
     
     
     
     
     
    Managing Member
     
     
     
     
    Dated: November 14, 2024
     
     
     
     
     
    Two Seas Capital GP LLC
     
     
     
     
     
     
     
     
     
     
    By: /s/ Sina Toussi
     
     
     
     
     
     
    Sina Toussi
     
     
     
     
     
     
    Managing Member
     
     
     
     
    Dated: November 14, 2024
     
     
     
     
     
    Sina Toussi
     
     
     
     
     
     
     
     
     
     
    By: /s/ Sina Toussi

    Get the next $ABUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABUS

    DatePrice TargetRatingAnalyst
    3/4/2022$5.50 → $6.00Buy
    Chardan Capital
    2/2/2022$4.00 → $5.00Hold → Buy
    Jefferies
    11/8/2021$7.00 → $9.00Market Outperform
    JMP Securities
    More analyst ratings

    $ABUS
    Financials

    Live finance-specific insights

    See more
    • Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase 1a/1b clinical trial were generally safe and well-tolerated with evidence of receptor occupancy Now dosing cHBV patients with AB-101 in Part 3 of the Phase 1a/1b clinical trial Cash runway into the fourth quarter of 2026Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a f

      11/6/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update

      WARMINSTER, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS), ("Arbutus" or the "Company") a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its third quarter 2024 financial results and corporate update for Wednesday, November 6, 2024. The schedule for the press release and conference call/webcast are as follows: • Q3 2024 Press Release:Wednesday, November 6, 2024 at 7:30 a.m. ET• Q3 2024 Conference Call/Webcast:Wednesday, November 6, 2024 at 8:45 a.m. ET   To dial-in for the conference call

      10/23/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      End-of-treatment data presented at the EASL Congress from two Phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a HBV functional cure treatment regimen IM-PROVE I clinical trial demonstrated undetectable HBsAg in 33% of patients who were treated with 48 weeks of imdusiran and 24 weeks of IFN and in 67% of these patients with baseline HBsAg less than 1000 IU/mL Prioritizing imdusiran Phase 2b clinical development; eliminating HBV discovery efforts resulting in a reduction in workforce by 40% and extension of expected cash runway into the fourth quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 01, 2024 (GLOBE

      8/1/24 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

      Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi

      5/7/25 2:01:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

      BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries. Genevant and Arbutus are seeking

      3/3/25 9:15:00 AM ET
      $ABUS
      $ROIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4/A - Arbutus Biopharma Corp (0001447028) (Issuer)

      4/1/25 5:47:47 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Nguyen Tuan

      4 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:24:03 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nguyen Tuan

      3 - Arbutus Biopharma Corp (0001447028) (Issuer)

      3/31/25 4:21:38 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Leadership Updates

    Live Leadership Updates

    See more
    • Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

      Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued focus on efficient deployment of financial resources and personnel – terminated ATM program and implemented reduction of workforce by 57% in Q1 2025 Board has approved further changes to executive leadership team; including the appointment of Tuan Nguyen as Chief Financial Officer Strong financial position with cash, cash equivalents and investments in marketable securities of $123M WARMINSTER, Pa., March 27, 2025 (GLO

      3/27/25 7:30:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

      WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) --  Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski replaces Michael J. McElhaugh, the Company's Interim President and CEO, effective immediately. Ms. Androski will also serve as a member of the Company's board of directors. Ms. Androski is an MIT-trained biologist with nearly 30 years of experience in the areas of biotechnology, law and academia. She has served in a variety of roles at Roivant. She

      2/25/25 7:00:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024

      WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that after a distinguished 38-year career, the Company's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024. Dr. Sofia is a globally recognized, Lasker award-winning antiviral drug discovery and development scientist. "On behalf of the entire Company, I want to thank Mike, a renowned industry veteran, for his tremendous contribu

      5/2/24 7:25:00 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    SEC Filings

    See more
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      5/7/25 6:00:14 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Arbutus Biopharma Corp (0001447028) (Filer)

      4/23/25 6:00:14 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Arbutus Biopharma Corporation

      DEFA14A - Arbutus Biopharma Corp (0001447028) (Filer)

      4/4/25 4:06:26 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Arbutus Biopharma with a new price target

      Chardan Capital reiterated coverage of Arbutus Biopharma with a rating of Buy and set a new price target of $6.00 from $5.50 previously

      3/4/22 8:38:50 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arbutus Biopharma upgraded by Jefferies with a new price target

      Jefferies upgraded Arbutus Biopharma from Hold to Buy and set a new price target of $5.00 from $4.00 previously

      2/2/22 5:11:07 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Arbutus Biopharma with a new price target

      JMP Securities reiterated coverage of Arbutus Biopharma with a rating of Market Outperform and set a new price target of $9.00 from $7.00 previously

      11/8/21 7:11:01 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Arbutus Biopharma Corporation

      SC 13G/A - Arbutus Biopharma Corp (0001447028) (Subject)

      11/14/24 8:41:06 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Arbutus Biopharma Corporation

      SC 13G - Arbutus Biopharma Corp (0001447028) (Subject)

      6/10/24 4:50:25 PM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Arbutus Biopharma Corporation (Amendment)

      SC 13D/A - Arbutus Biopharma Corp (0001447028) (Subject)

      5/17/24 9:03:23 AM ET
      $ABUS
      Biotechnology: Pharmaceutical Preparations
      Health Care